With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.
Lawmakers have requested data and documents from the FDA related to the agency's controversial approval of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm.